# Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

> **NCT06017297** · PHASE2 · WITHDRAWN · sponsor: **Georgetown University**

## Conditions studied

- Borderline Resectable Carcinoma
- Biliary Tract Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **PROCEDURE:** Surgical Resection

## Key facts

- **NCT ID:** NCT06017297
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision and challenges in finding eligible participants
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06017297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06017297, "Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06017297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*